Ocular Therapeutix (NASDAQ:OCUL) Trading Up 5.3%

Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report)'s stock price was up 5.3% on Thursday . The company traded as high as $8.92 and last traded at $8.90. Approximately 89,801 shares traded hands during trading, a decline of 96% from the average daily volume of 2,018,726 shares. The stock had previously closed at $8.45.

Analyst Ratings Changes

A number of equities analysts recently commented on OCUL shares. StockNews.com raised shares of Ocular Therapeutix from a "sell" rating to a "hold" rating in a research note on Monday, March 18th. JMP Securities reaffirmed a "market outperform" rating and issued a $24.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, March 13th. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, February 14th. Piper Sandler raised their price objective on shares of Ocular Therapeutix from $10.00 to $15.00 and gave the stock an "overweight" rating in a research note on Monday, February 26th. Finally, Bank of America assumed coverage on shares of Ocular Therapeutix in a research report on Friday, February 9th. They issued a "buy" rating and a $15.00 target price for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Ocular Therapeutix currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.80.

Ocular Therapeutix Stock Up 0.2 %

The stock has a market cap of $1.26 billion, a P/E ratio of -6.78 and a beta of 1.30. The company has a current ratio of 6.66, a quick ratio of 6.59 and a debt-to-equity ratio of 0.82. The firm's fifty day moving average is $8.20 and its 200 day moving average is $4.98.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last posted its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). The company had revenue of $14.80 million for the quarter, compared to analyst estimates of $15.31 million. Ocular Therapeutix had a negative net margin of 138.15% and a negative return on equity of 321.12%. As a group, equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.68 EPS for the current year.

Insider Activity

In other Ocular Therapeutix news, CFO Donald Notman sold 6,433 shares of the business's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total value of $31,843.35. Following the transaction, the chief financial officer now directly owns 139,932 shares in the company, valued at $692,663.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Ocular Therapeutix news, CFO Donald Notman sold 6,433 shares of the business's stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $4.95, for a total value of $31,843.35. Following the completion of the transaction, the chief financial officer now directly owns 139,932 shares of the company's stock, valued at $692,663.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Philip C. Strassburger sold 6,831 shares of the business's stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $4.95, for a total transaction of $33,813.45. Following the completion of the transaction, the general counsel now directly owns 109,218 shares of the company's stock, valued at $540,629.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 39,366 shares of company stock worth $194,862. Corporate insiders own 5.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC raised its position in shares of Ocular Therapeutix by 84.4% in the first quarter. FMR LLC now owns 4,751 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 2,175 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in Ocular Therapeutix by 61.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 9,225 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 3,500 shares during the period. Trust Co. of Vermont increased its holdings in Ocular Therapeutix by 20.0% in the 4th quarter. Trust Co. of Vermont now owns 6,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,000 shares during the period. Rafferty Asset Management LLC bought a new position in Ocular Therapeutix in the 3rd quarter valued at about $37,000. Finally, SG Americas Securities LLC bought a new position in Ocular Therapeutix in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 59.21% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.